Jonathan R Dry

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010

Detail Information

Publications1

  1. ncbi Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010
    ..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...